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1 ABSTRACT IN ENGLISH 
 
Charles University 
Faculty of Pharmacy in Hradec Králové 
Department of Biological and Medical Sciences  
Supervisors:  prof. Dr. Michael Gütschow 
 RNDr. Klára Konečná, Ph.D. 
Candidate:  Michaela Hympánová 
Title of the diploma thesis: Enzyme kinetic evaluation of several potential inhibitors of 
certain human cysteine and serine proteases 
 
Background  
 Cysteine and serine proteases are enzymes involved in many physiological 
processes. The imbalance between them and their endogenous inhibitors is associated 
with various diseases such as cancer and osteoporosis. Synthetic inactivators could be 
useful in the treatment of these enzyme-mediated pathological conditions. Therefore, 
there are ongoing attempts to develop low-molecular weight inactivators for 
therapeutically relevant cysteine and serine proteases. In the course of this thesis, 
compounds synthesized in prof. Gütschow's group were investigated as potential 
inhibitors of selected human proteases. They belong to imidazole compounds derived 
from N-protected cyclohexylalanine, 2-phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-
6(5H)-one derivatives, ,-unsaturated peptidomimetic compounds, carbamates, an 
N,N-dibenzylcrotonamide derivatives and peptoides. 
 
Aims 
 This diploma thesis has been focused on the evaluation of new potential 
inhibitors against human cathepsins B, L, S and K, which belong to cysteine proteases, 
as well as representatives of serine proteases, human leukocyte elastase and human 
thrombin. Furthermore, the structure-activity relationships of a small series of low 
molecular weight compounds were investigated.  
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Methods 
 In the experimental part, enzyme inhibition assays and their corresponding 
kinetic evaluation was introduced. In the course of this project, a human leukocyte 
elastase inhibition assay was modified and the determination of the Michaelis-Menten 
constant (KM) was performed. Based on the obtained data, the inhibitory potency of the 
tested inhibitors was characterized by methods of linear and non-linear regression 
analysis to calculate different inhibition parameters.  
 
Results 
 Most of the imidazole derivatives have shown significant inhibition against 
human leukocyte elastase. The best inhibitor from this group has been compound 3161 
(IC50 (1 + [S] 𝐾M⁄ )⁄  = 0.60 ± 0.03 µM) containing a methyl- and phenyl-substituted 
imidazole moiety. Carbamate 3167 (kinac/Ki = 12.44 µM
-1s-1) was considered as an 
irreversible cathepsin B inhibitor. The N,N-dibenzylcrotonamide derivative, compound 
3110 (kinac/Ki = 2292.8 ± 240.74 µM
-1s-1) containing an -unsaturated Michael 
acceptor substructure, was considered as an irreversible inhibitor of cathepsin K. All 
other investigated compounds did not show any inhibitory potency. 
 
Conclusion 
 In summary, some potent inhibitors of some tested enzymes have been found. 
The imidazole derivatives proved reversible inhibitory potential against human 
leukocyte elastase. Results with compound 3167 confirmed that the introduction of a 
carbamate structure is a possible way for the development of new cathepsin B 
inhibitors. The N,N-dibenzylcrotonamide derivative (compound 3110) demonstrated the 
potential of Michael acceptors as irreversible cathepsin K inhibitors. Further analogous 
compounds need to be investigated in the future.  
 
Key words: cathepsins, cysteine proteases, serine proteases, enzyme kinetics, enzyme 
inhibition  
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2 ABSTRACT IN CZECH 
 
Univerzita Karlova 
Farmaceutická fakulta v Hradci Králové 
Katedra biologických a lékařských věd 
Školitelé:  prof. Dr. Michael Gütschow 
 RNDr. Klára Konečná, Ph.D. 
Kandidát:  Michaela Hympánová 
Název diplomové práce: Hodnocení enzymové kinetiky několika potenciálních 
inhibitorů lidských proteáz cysteinového a serinového typu 
 
Úvod 
 Enzymy řadící se mezi cysteinové a serinové proteázy jsou součástí mnoha 
fyziologických procesů. Nerovnováha mezi enzymy a jejich endogenními inhibitory 
patří mezi faktory účastnící se rozvoje řady chorob, například nádorových onemocnění 
nebo osteoporózy. Syntetické inaktivátory by proto mohly být užitečné v léčbě těchto 
patologických stavů. Některé látky jsou již ve vývoji a dohledatelné v literatuře. 
Náplní této diplomové práce je hodnocení inhibičního potenciálu látek syntetizovaných 
skupinou prof. Gütschowa proti vybraným lidským proteázám. Testované látky patří 
mezi imidazolové sloučeniny pocházející z N-chráněného cyclohexylalaninu, 
sloučeniny získané substitucí 2-phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-onu, 
-nenasycené peptidomimetické sloučeniny, karbamáty, deriváty N,N-dibenzyl-
krotonamidu a peptoidy. 
 
Cíle 
 Cílem této diplomové práce bylo zhodnotit nové potenciální inhibitory pomocí 
testování na katepsinech B, L, S a K, které jsou zástupci cysteinových proteáz  
a na lidské leukocytární elastáze a trombinu, jakožto zástupcích serinových proteáz. 
Dalším cílem bylo najít vztahy mezi strukturou látek a potenciálním účinkem. 
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Metodika 
 Součástí experimentální části byly metody vedoucí k měření a hodnocení 
enzymové inhibice. V průběhu experimentu bylo třeba modifikovat metodu měření 
enzymové aktivity lidské leukocytární elastázy a zároveň stanovit novou Michaelisovu 
konstantu (KM) při změněných podmínkách. Na základě získaných dat byly testované 




 Většina imidazolových derivátů se prokázala jako reverzibilní inhibitory lidské 
leukocytární elastázy. Nejsilnější inhibiční účinek z této skupiny měla sloučenina 3161 
(IC50 (1 + [S] 𝐾M⁄ )⁄  = 0.60 ± 0.03 µM) obsahující imidazol substituovaný fenylem  
a methylem. Karbamát 3167 (kinac/Ki = 12.44 µM
-1s-1) lze po provedené analýze 
považovat za ireversibilní inhibitor katepsinu B. Derivát N,N-dibenzylkrotonamidu, 
látka 3110 (kinac/Ki = 2292.8 ± 240.74 µM
-1s-1) obsahující ve své struktuře  
-nenasycený Michaelův akceptor, může být považována za ireverzibilní inhibitor 
katepsinu K. Všechny ostatní testované látky neprokázaly inhibiční potenciál. 
 
Závěr 
 Závěrem můžeme říct, že mezi testovanými látkami byly nalezeny inhibitory 
některých cílových enzymů. Látky ze skupiny imidazolových derivátů prokázaly 
reverzibilní inhibiční potenciál proti lidské leukocytární elastáze. Karbamát 3167 
poukázal, že sloučeniny tohoto typu by mohly být cestou ve vývoji inhibitorů katepsinu 
B. Derivát N,N-dibenzylkrotonamidu 3110 potvrdil potenciál Michaelova akceptoru 
jako struktury vhodné u ireverzibilních inhibitorů katepsinu K. Další látky analogické 
k výše testovaným by měly být syntetizovány a podrobeny enzymatickým testům. 
 
 
Klíčová slova: katepsiny, cysteinové proteázy, serinové proteázy, enzymová kinetika, 
enzymová inhibice 
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3 LIST OF ABBREVIATIONS 
Ki dissociation constant for enzyme-inhibitor-substrate complex and free 
inhibitor and enzyme-substrate complex 







BMD bone mineral density 
Brij. 35 polyethylene glycol dodecyl ether 
cat B cathepsin B 
cat K cathepsin K 
cat L cathepsin L 
cat S cathepsin S 
Cys cysteine 
d offset 
DMSO dimethyl sulfoxide 
DTT dithiothreitol 
E enzyme 






HLE human leukocyte elastase 
HT human thrombin 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate 
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[I] concentration of inhibitor 
IC50 half-maximal inhibitory concentration 
Ki inhibition constant 
kinac first-order rate constant of inactivation 
kobs observed first-order rate constant 
KM Michaelis-Menten constant 




MES 2-(N-morpholino)ethanesulfonic acid 
ODN odanacatib 




[S] concentration of the substrate 
S substrate 




v reaction rate ‒ relative activity of enzyme 
v0 reaction rate in absence of inhibitor 
vi initial rate 
vmax maximum velocity at infinite substrate concentration 
vs plotting reaction rate ‒ steady-state velocity 
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4 THE ASSIGNMENT OF DIPLOMA THESIS – OBJECTIVE 
The aim of this work was to evaluate the inhibitory potency of several compounds 
against human cathepsins B, L, S, K, which belong to cysteine proteases, as well as 
representatives of serine proteases, human leukocyte elastase and human thrombin.  
It was intended to determinate the structure-activity relationships for small series of low 
molecular weight compounds. Selective inhibitors could be useful in the treatment of 
these enzyme-mediated pathological conditions. Moreover, this study was aimed at 
employing several methods of enzyme kinetic analyses to obtain appropriate kinetic 
parameters for the observed inhibitory events. 
The theoretical part will focus on certain cysteine and serine proteases in 
general and their therapeutic importance and reasons for development of inhibitors. 
The experimental work will include six enzymatic assays for cathepsins B, L, K, S, 
as well as human leukocyte elastase and human thrombin. Based on the obtained data, 
the evaluation of the inhibitory activity of the several potential inhibitors will be 
performed by the analysis of the progress curves. Biochemical parameters of enzyme 
inhibition will be obtained by methods of linear and non-linear regression analysis. 
Finally, it is intended to draw structure-activity-relationships for small series of tested 
low-molecular weight compounds. 
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5 INTRODUCTION 
 This thesis is focused on representatives of cysteine and serine proteases, exactly 
on cathepsins B, L, K, S, human leukocyte elastase and human thrombin. These 
enzymes are involved in many physiological processes. The imbalance between them 
and their endogenous inhibitors is associated with various diseases.1,2 Synthetic 
inhibitors could be useful in treatment of these pathological conditions. Even according 
to literature, some inhibitors had already reached clinical trials.3,4 
 In the course of this project potential inhibitors were analyzed by enzyme 
inhibition assays and their corresponding kinetic evaluation.  
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6 THEORETICAL PART 
6.1 Proteases 
 Proteases constitute a large group of enzymes capable of catalyzing the 
hydrolysis of peptide bonds in proteins. They can be classified according to the active 
site residue of the catalytic triad, i.e. serine, cysteine, threonine, aspartyl, glutamic, and 
metallopeptidases. The proteases can be also divided into exopeptidases and 
endopeptidases depending on the location of the cleavage within a peptide sequence. 
Classification according to the role in the organism divides proteases as either 
degradative, which means that the hydrolysis of peptide bonds leads to complete 
breakdown of the targeted protein, or regulatory, which means that cleavage of one or 
more specific bonds alters the biological activity of the targeted protein.5,6 
Proteases have indispensable roles in various biological processes. In 
mammalian cells, they are involved in angiogenesis, apoptosis, cell differentiation, 
immune response, matrix remodeling and protein activation. Imbalance of the enzymes 
and their endogenous inhibition mechanisms is associated with a number of diseases, 
including cardiovascular and Alzheimer's disease, cancer, autoimmune diseases, 
inflammation, and hypertension.7 This provides the impetus behind the development of 
new enzyme inhibitors. 
Proteolytic enzymes interact with their specific substrates through the specific 
binding of an amino acid residue with the enzyme's subsites. According to Schechter 
and Berger nomenclature P1-P1' denotes peptide residues on the acyl and leaving group 
side of the scissile bond. S1-S1' designate the corresponding subsites of the protease.8 
Serine and cysteine proteases act directly as nucleophiles by using their catalytic 
triad to attack an amide carbonyl carbon.5,6 The cleavage mechanism, a general two-step 
acyl transfer, is described for the cysteine proteases as follows (Figure 1). The acylation 
part is initiated by the nucleophilic attack of the thiolate cysteine (A) at the carbonyl 
carbon of the scissile bond (B) and forms the first tetrahedral intermediate (C) stabilized 
by the oxyanion hole. The tetrahedral intermediate transforms into an acyl-enzyme (E) 
with the simultaneous release of the C-terminal portion of the substrate (D). In the 
subsequent deacylation part, the thiol ester bond of the acyl enzyme is hydrolyzed 
through the second tetrahedral intermediate (F) which splits into the free enzyme (A) 
and the N-terminal portion of the substrate (G).9,10 




Figure 1: Cysteine protease catalytic mechanism.  
The scheme was created by the author of the thesis according to the literature 
sources.9,10  Detailed description of the scheme is situated in the previous paragraph.  
 
6.1.1 Cysteine proteases 
 It has been described 11 human cathepsins B, C, F, H, K, L, O, S, V, W, and X 
belonging to cysteine proteases.5,11 The catalytic machinery relies on cysteine-25, 
histidine-159, and asparagine-175 (papain numbering system).5,8 Cysteine and histidine 
forms an ion pair essential for the proteolytic activity of the enzyme and this is 
stabilized by arginine via a hydrogen bond (Figure 2).1,9 Human cathepsins are  
pH-labile cysteine proteases found primarily in lysosomes. The optimum pH for them is 
slightly acidic, which allows full activity within the lysosomal compartment.1,9,12 
Lysosomal cathepsins are regulated by zymogen activation and by endogenous protein 
inhibitors.1 An increase in the level of cathepsin expression and activity is implicated in 
the development of neurological disorders, cardiovascular diseases, inflammatory 
diseases such as rheumatoid arthritis, cancer and others.1,9 
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 Cathepsin B (cat B) has an occluding loop with two histidine residues which 
anchors the C-terminal carboxyl group of a substrate. This structure moiety is unique 
among cathepsins and is related to the endo and exopeptidase activity of cat B.5 The 
endopeptidase activity of cat B depends on the flexibility of the occluding loop. 
Removal of the occluding loop leads to the significant increase in the endopeptidase 
activity of cat B.9 
Cathepsin L (cat L) is required in development of hair follicles and skin 
epidermis, for cardiac morphology and function or for the positive T-cell selection in 
the thymus.1 On the other hand, cat L is involved in tumor invasion by degradation of 
the extracellular matrix and the basal membrane.6 
Cathepsin S (cat S) and cathepsin K (cat K) show a restricted cell or tissue-
specific distribution, which is related to more specific roles in organism.1 Cat S is 
selectively expressed in lymphatic tissues and involved in antigen presentation.1,9 
Cat K is expressed in osteoclasts, in most epithelial cells and in the synovial 
fibroblasts in rheumatoid arthritis joints.1,9 The critical role of cat K in bone remodeling 
is collaborated by the autosomal recessive bone sclerosing disorder, pycnodysostosis 
(the human form of cat K deficiency) or osteoporosis.9 
 
 
Figure 2: Cysteine protease mechanism. 
Catalytic triad is formed by cysteine (Cys), histidine (His) and asparagine (Asn). The 
nucleophilic attack by the active site cysteine residue in the carbonyl carbon of the 
scissile bond. The scheme was taken from Erez e t. al., 2009.13 
6.1.2 Serine proteases 
 The class of serine proteases is generally well known in the proteases family. 
Their catalytic triad consists of serine-195, histidine-57, aspartate-102 (papain 
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numbering system) and its mechanism is comparable to the above mentioned class of 
cysteine proteases. The nucleophilic attack is executed by the active site serine residue 
in the carbonyl carbon of the scissile bond (Figure 3). Well-studied members are 
chymotrypsin, trypsin, elastase, and subtilisin, of which the chymotrypsin-like proteases 
human leukocyte elastase (HLE) and human thrombin (HT) have been investigated in 
this thesis.2,7 These enzymes are part of many critical physiological processes such as 
digestion, hemostasis, and apoptosis.2 
 HLE is stored in azurophilic granules of neutrophils and capable of breaking 
down components of the extracellular matrix and foreign proteins. It plays an important 
role in the innate immune response, in tissue remodeling processes, and in the onset and 
resolution of inflammation. Out-of-balance HLE activity is associated with many 
inflammatory diseases, such as chronic obstructive pulmonary disease, adult respiratory 
distress syndrome or cystic fibrosis.14,15 
 HT plays an important role in coagulation, anticoagulation and fibrinolysis.16 
The anticoagulation therapy is a main part of modern medical therapy for 
cardiovascular and thrombotic diseases. Direct HT inhibitors are a class of 
anticoagulants that binds directly to HT and inhibits its interaction with substrates.17 
Recombinant hirudins belong to parenteral direct HT inhibitors. Dabigatran represents 
an oral specific and reversible inhibitor.18 
 
Figure 3: Serine protease mechanism. 
Catalytic triad is formed by serine (Ser), histidine (His) and aspartate (Asp). The 
nucleophilic attack by the active site serine residue in the carbonyl carbon of the scissile 
bond. The scheme was taken from Erez et. al., 2009.13 
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6.2 Enzyme inhibitors in drug development 
 Enzymes are commonly the target of new drug discovery, thanks to their 
essential roles in many diseases. The active site of the enzymes, responsible for the 
catalytic activity, can often be inhibited by small molecules. Enzyme inhibitors 
represent almost half of the drugs in the clinical use today. A few examples are given in 
Table 1.19 
Table 1: Selected enzyme inhibitors in clinical use.19 
Compound Target enzyme Clinical use 










Omeprazole H+, K+ ATPase Peptic ulcers 
 
 The examples of direct HT inhibitors, as participating enzyme in this thesis, are 
previously mentioned to be recombinant hirudins and dabigatran as anticoagulants.18 
Sivelestat, as HLE inhibitor, reached a phase IV study in treatment of acute lung injury 
associated with systemic inflammatory response syndrome.4 Some other research 
groups have published articles about their work with potentials HLE inhibitors.20,21 
Based on known literature, no inhibitors of cathepsins B, L, S and K are in clinical use. 
Most progress was found in the field of drug development of cat K inhibitors. The 
importance of cat K in bone resorption led to the assumption that specific cat 
K inhibitors will be beneficial in the treatment of osteoporosis.9 For example, balicatib 
(Figure 4) has been subjected to phase II clinical trials. Favorable effects on the 
reduction of relevant biochemical markers of bone resorption and an increase in bone 
mineral density was observed. Besides this, also skin adverse events as pruritus, rashes 
and rare morphea-like skin changes were manifested. Another promising compound, 
odanacatib (ODN) (Figure 4), underwent clinical trials within the last years which will 
be shortly introduced in the next chapter.22 




Figure 4: Left: chemical structure of balicatib.23 Right: chemical structure of 
odanacatib.3 
6.3 Cathepsin K inhibitors and osteoporosis  
 In the human skeleton, there is normally a balance between bone resorption and 
formation.24 Osteoporotic bones are characterized by increased bone resorption and 
diminished bone formation, which leads to a reduction in bone mineral density (BMD) 
and increases the risk of developing fractures.25 During the bone resorption, osteoclasts 
secrete protons onto the bone surface, which causes demineralization of the membrane. 
Further, cat K disrupts an exposed organic matrix primarily containing collagen  
type 1.26 A simplified scheme of bone resorption is given in Figure 5. 
 
 
Figure 5: Bone resorption.  
Protons secreted by osteoclasts causes demineralization of the bone surface membrane. 
Cathepsin K (cat K) disrupts an exposed organic matrix. The Figure was created by the 
author of the thesis according to the literature sources.24,26  
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 The selective inhibitor of cat K, odanacatib, was developed for osteoporosis 
treatment on postmenopausal women with low BMD.27–33 In the following paragraphs, 
the results of clinical trials in phases II and III are described. 
 In the phase II clinical trial, the drug is first administered to a small number of 
patients and the main emphasis is given on safety and efficiency. The therapeutic effects 
are demonstrated, a suitable dose is sought, and additional drug data are collected.34 
 For this purpose, four follow-up studies were conducted of weekly oral ODN (up 
50 mg) for up to 8 years. BMD and biomarkers of skeletal remodeling were observed. 
Two last study extensions up to 5 and 8 years had limitations because of the small 
number of patients remaining in each treatment group, which prevented formal 
statistical analysis, as originally described in the study design. The lack of 
randomization (patients were carried over from their originally assigned treatment) and 
the open-label nature of this extension may have caused additional bias. These clinical 
trials had shown a dose-dependent increase in BDM at multiple sites. Improvements in 
BMD were generally greatest in those patients who had received continuous ODN 
50 mg for the longest period of time. Whereas bone resorption markers remained 
reduced, no significant change was observed in bone formation markers. During the 
first 6 months, ODN transiently suppresses bone-formation markers. They returned to 
baseline levels by the end of second year despite continued treatment and both remained 
at or near baseline during the third year of treatment. Other osteoclast activities did not 
appear to be greatly affected. Inhibition of cat K enzyme activity by ODN is a reversible 
process and BMD returns to baseline levels or slightly below after discontinuation of 
treatment.27–30 Results of treatment with the 3 mg dose of ODN were contrary to 
expectations and contrary to what was observed at higher doses. An accelerated bone 
turnover was observed and the BMD results were similar to placebo. The lack of benefit 
from the 3 mg weekly dose may have resulted from insufficiently sustained suppression 
of cat K throughout the duration of the weekly dosing interval. As such, this had been a 
theoretical concern in patients, who had been noncompliant with the standard dose or 
who had had faster drug metabolism.28 
Phase III trial typically involves hundreds to thousands of patients in order to 
verify the efficiency and to get more information about the safety.34 
For this purpose, the next 2-years trial with 214 postmenopausal women with 
low BMD had been performed. In women treated weekly by 50 mg for 2 years, ODN 
demonstrated a consistent effect relative to placebo.31 Another long-term ODN phase III 
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trial was performed on more than 16,000 postmenopausal women with low BMD. 
Patients had received ODN 50 mg for 3 years. The study showed a robust reduction in 
fracture incidence. The trial was stopped early after a planned analysis had shown 
robust efficacy and a favorable benefit/risk profile.32 
Unfortunately, analysis of clinical data showed that while ODN had been indeed 
effective, it also increased the risk of a stroke. In September 2016, Merck announced 
that they discontinued the development of the compound.33 
Despite the above-mentioned compounds eventually failed in their trials, the 
path of possible success did not end here. Research groups such as the one of prof. 
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7 EXPERIMENTAL PART 
7.1 Material  
 Substrates Z-Arg-Arg-pNA, Z-Phe-Arg-pNA, Z-Leu-Arg-AMC, Z-Phe-Arg-
AMC and Z-Gly-Gly-Arg-AMC were purchased from Bachem (Switzerland). Substrate 
MeO-Suc-Ala-Ala-Pro-Val-pNA was obtained from abcr GmbH (Germany). Used 
abbreviations can be found in the list of abbreviations at the page 10. 
 Human cat B was purchased from Calbiochem (Germany). Human cat L and 
cat K and human recombinant cat S were obtained from Enzo Life Science (Germany).  
 NaH2PO4 and Na2HPO4 for sodium phosphate buffer, citric acid and trisodium 
citrate for sodium citrate buffer, NaCl and dimethyl sulfoxide (DMSO) were  
obtained from Fisher Scientific. Polyethylene glycol dodecyl ether (Brij. 35),  
3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS), 
Triton-X, ethylenediaminetetraacetic acid (EDTA) from Applichem GmbH (Germany). 
2-(N-morpholino)ethanesulfonic acid (MES), dithiotreitol (DTT) from Carl Roth GmbH 
(Germany). 
 96-well plate with flat bottom, pipette tips 0.2-20 µL, 20-200 µL, 100-100 µL 
were purchased from Sarstedt (USA). Plastic Eppendorf tubes, spatulas for mixing and 
disposable cuvettes Carl Roth were obtained from GmbH (Germany). 
7.2 Instruments 
 Fluorometric assays were performed in a using a FLUOstar Optima (BMG 
LABTECH, Germany). A Cary® 50 UV-Vis (Varian, INC., Agilent Technologies, 
Nederland) spectrophotometer was used for spectrophotometric measurements. 
7.3 Methods 
 Compounds were investigated with concentration 5 µM or 1 µM (depending on 
solubility) in duplicates. In case of obtained inhibition 5 different inhibitor 
concentrations were investigated in duplicates or with 10 different inhibitor 
concentrations in a single measurement. Depending on the type of inhibition, the 
obtained progress curves were analyzed by linear or non-linear regression. 
 At first frozen enzymes were activated. Liquid cathepsins B, L, K and S were 
diluted and incubated with activating buffer under the certain condition according to 
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each assay instruction. In case of HT and HLE, only dilution with assay buffer was 
performed. Activated enzymes were always kept in a box with ice. An exception was 
direct dilution of HLE before every measurement, because of the fast activity decrease 
of this enzyme. 
 Stock solution of the substrates and inhibitors were always prepared in DMSO. 
The exception was one more dilution of substrate in HLE assay with DMSO and assay 
buffer. 
 In every spectrometric or fluorometric measurement cuvettes or well plates were 
prepared in the same order (Figure 6). The assay buffer, DMSO, inhibitor and substrate 
stock solution were added in this order and volume was subsequently mixed. Enzyme 
was added as the last one and volume was again thoroughly mixed. 
 Every measurement had two controls containing everything without inhibitor. 
Duplicate measurements were made in different runs under the same conditions.  
 For easier orientation in cuvettes or well plates preparation, it was advisable to 
prepare a table containing volume of individual substances (example in Table 2). 
 Detailed descriptions of each assay are given in the following paragraphs. 
 
 
Figure 6: Scheme of assays. 
The enzymes belonging to this thesis were stored in the refrigerator. For an enzymatic 
activation they were incubated under certain conditions in the incubator. The cuvettes 
were subsequently filled up by assay buffer, dimethyl sulfoxide (DMSO), inhibitor (I) 
and substrate stock solution (S) in this order. The volume was subsequently mixed and 
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the enzyme was added as the last one. The volume was thoroughly mixed again and 
cuvettes were given into the spectrophotometer and well plate into the fluorometer. 
Measurements were performed under certain conditions according to each enzymatic 
assay (described in the following paragraphs).  The scheme was created by the author of 
the thesis. 













Control 960 15 0 5 20 
Inhibitor 
5 µM 
940 14.5 0.5 5 20 
The example of table containing the correct volume of the each substance according to 
cathepsin B assay for measurement of control inhibitor at concentration of 5 µM. Table 
was made by the author of the thesis. 
7.3.1 Mechanism of detection 
The activity of the enzyme is based on the absorbance or fluorescence of the formed 
product. During the spectrophotometric measurement, para-nitroaniline (pNA) is 
cleaved from the chromogenic substrate by the enzyme. Absorbance of yellow pNA is 
observed, and according to Lambert-Beer law, is directly equal to the product 
concentration. In the fluorescence method, the fluorophore 7-amino-4-methylcoumarine 
(AMC) is the part cleaved by enzyme from the fluorogenic substrate. Amino acids in 
the individual substrates are selected according to the preferences of the individual 
enzyme. The schematic equations of the reactions are shown in Figure 7. 
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Figure 7: Scheme of enzyme reactions.  
A, B: Spectrophotometric reaction mechanism performed with human leukocyte 
elastase (HLE), cathepsin B (cat B) and cathepsin L (cat L). Yellow para-nitroaniline 
(pNA) is released from the substrate after enzymatic cleavage. C, D: Fluorescent 
reaction mechanism performed with cathepsin K (cat K) and cathepsin S (cat S), as well 
as HT. Fluorescent 7-amino-4-methylcoumarineis (AMC) is released from the substrate 
after enzyme cleavage. Z is representing the carboxybenzyl as an amine protecting 
group. Abbreviations of amino acids are described in the list of abbreviations (page 10). 
The Figure was created by the author of the thesis. 
7.3.2 Human cathepsin B inhibition assay 
 The cathepsin B assay35 was based on spectrophotometric measurements of the 
released pNA at wavelength 405 nm and 37 ºC (the reaction scheme in Figure 7, page 
25).  
 The assay buffer was composed of 100 mM sodium phosphate buffer (pH 6.0), 
100 mM NaCl, 5 mM EDTA and 0.01% Brij. 35.  
 The enzyme stock solution of the human cathepsin B with the concentration of 
0.47 mg/mL was prepared in 20 mM sodium acetate buffer (pH 5.0) and 1 mM EDTA 
and kept at 0°C.  
 The substrate Z-Arg-Arg-pNA stock solution with the concentration of 100 mM 
was made in DMSO.  
 The inhibitor stock solution was prepared in DMSO. 
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 At first the enzyme was activated according to subsequent process. The enzyme 
stock solution was diluted in proportion 1:500 in assay buffer additionally containing 
5 mM DTT and was incubated for 30 min at 37 ºC. 
  Subsequently cuvettes were prepared. Each cuvette contained 960 μL of the 
assay buffer, 15 µL of the inhibitor solution and DMSO in total and 5 μL of the 
substrate solution. Then the cuvette volume was mixed and the catalytic transformation 
of the substrate started after adding 20 μL of the activated enzyme solution. The 
conclusive concentration of the substrate was 500 μM (= 0.45 KM), while the conclusive 
concentration of cathepsin B was 18.8 ng/mL and 2 % of the DMSO in the cuvette. The 
value of KM was taken from the original assay.
35 The reactions were followed over 
60 min. All experiments were performed in duplicates.  
7.3.3 Human cathepsin L inhibition assay 
 The cathepsin L assay35 was based on spectrophotometric measurements of the 
released pNA at wavelength 405 nm and 37 ºC (the reaction scheme in Figure 7, page 
25).  
 The assay buffer was composed of 100 mM sodium phosphate buffer pH 6.0, 
100 mM NaCl, 5 mM EDTA and 0.01% Brij 35.  
 The enzyme stock solution of human cathepsin L with the concentration of 
135 μg/mL was prepared in 20 mM malonate buffer pH 5.5, 400 mM NaCl, and 1 mM 
EDTA and kept at 0°C. 
 The substrate Z-Phe-Arg-pNA stock solution with the concentration of 10 mM 
was made in DMSO.  
 The inhibitor stock solution was prepared with DMSO.  
 At first the enzyme was activated according to subsequent process. The enzyme 
stock solution was diluted in proportion 1:100 in assay buffer additionally containing 
5 mM DTT and was incubated for 30 min at 37 ºC.  
 Subsequently the cuvettes were prepared. Each cuvette contained 940 μL of the 
assay buffer, 10 µL of the inhibitor solution and DMSO in total and 10 μL of the 
substrate solution. Then the cuvette volume was mixed and the catalytic transformation 
of the substrate started after adding 40 μL of the activated cathepsin L solution. The 
final concentration of the substrate was 100 μM (= 5.88 KM), the conclusive 
concentration of cathepsin L was 54 ng/mL and the final concentration of DMSO was 
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2 %. The value of KM was taken from the original assay.
35 The reactions were followed 
over 60 min. All experiments were performed in duplicates. 
7.3.4 Human cathepsin K inhibition assay 
 The cathepsin K assay35 was carried out fluorometrically at 25 °C in a 96-well 
plate with flat bottom with adjusted wavelength of 360 nm for excitation and 440 nm 
for emission (the reaction scheme in Figure 7, page 25).  
 The assay buffer consists of 100 mM sodium citrate pH 5.0, 100 mM NaCl, 
1 mM EDTA and 0.01% CHAPS. 
 The enzyme solution of human cathepsin K with the concentration of 23 μg/mL 
was prepared in 50 mM sodium acetate pH 5.5, 50 mM NaCl, 0.5 mM EDTA and 5 mM 
DTT and kept at 0°C. 
 The substrate Z-Leu-Arg-AMC stock solution with the concentration of 10 mM 
was made in DMSO. 
 The inhibitor stock solution was prepared with DMSO.  
 At first the enzyme was activated according to the subsequent process. The 
enzyme stock solution was diluted in proportion 1:100 in assay buffer additionally 
containing 5 mM DTT and was incubated for 30 min at 37 ºC.  
 Subsequently well plate was prepared. Into each well containing 192 μL of the 
assay buffer, 3.2 µL of the inhibitor solution and DMSO in total and 0.8 μL of the 
substrate solution were added and thoroughly mixed. The reaction was initiated by 
adding 4 μL of the activated cathepsin K solution. The final concentration of the 
substrate was 40 μM (= 13.3 KM), the conclusive concentration of cathepsin K was 5 
ng/mL and the final concentration of DMSO was 2 %. The value of KM was taken from 
the original assay.35  The reactions were followed over 60 min. All experiments were 
performed in duplicates. 
 
7.3.5 Human cathepsin S inhibition assay 
 Human recombinant cathepsin S36 was assayed fluorometrically at 25 °C in a  
96-well plate with flat bottom with adjusted wavelength of 360 nm for excitation and 
440 nm for emission (the reaction scheme in Figure 7, page 25).  
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 The assay buffer consists of 100 mM sodium phosphate buffer pH 6.0, 100 mM 
NaCl, 5 mM EDTA, and 0.01% Brij 35.  
 The enzyme solution of human recombinant cathepsin S with the concentration 
of 70 μg/mL was prepared in 100 mM MES buffer, pH 6.5, 1 mM EDTA, 50 mM  
L-cysteine, 10 mM DTT, 0.5% Triton X-100 and 30% glycerol and kept at 0 °C. 
 The substrate Z-Phe-Arg-AMC stock solution with the concentration of 10 mM 
was made in DMSO. 
 The inhibitor stock solution was prepared with DMSO.  
 At first the enzyme was activated according to subsequent process. The enzyme 
stock solution was diluted in proportion 1:100 in with another buffer containing 50 mM 
sodium phosphate buffer pH 6.5, 50 mM NaCl, 2 mM EDTA, 0.01% Triton X-100 and 
5 mM DTT and was incubated for 60 min at 37 ºC.  
 Subsequently well plate was prepared. Into each well containing 184 μL of the 
assay buffer, 3.2 µL of the inhibitor solution and DMSO in total and 0.8 μL of the 
substrate solution were added and thoroughly mixed. The reaction was initiated by 
adding 12 μL of the activated cathepsin S solution. The final concentration of the 
substrate was 40 μM (= 0.74 KM), the conclusive concentration of cathepsin S was 
42 ng/mL and the final concentration of DMSO was 2 %. The value of KM was taken 
from the original assay.36  The reactions were followed over 60 min. All experiments 
were performed in duplicates. 
7.3.6 Human thrombin inhibition assay 
 HT was assayed37 fluorometrically at 25 °C in a 96-well plate with flat bottom 
with adjusted wavelength of 340 nm for excitation and 460 nm for emission (the 
reaction scheme in Figure 7, page 25).  
 Assay buffer was 50 mM Tris-HCl, 150 mM NaCl, pH 8.0.  
 The enzyme solution of HT with the concentration of 1000 U/mL was prepared 
in water, kept at 0 °C and at the beginning of measurement was diluted with assay 
buffer. 
  A 10 mM stock solution of fluorogenic substrate Z-Gly-Gly-Arg-AMC in 
DMSO was diluted with assay buffer to concentration of 800 µM. 
 Into each well containing 173.8 µL assay buffer, 11.2 µL of the inhibitor 
solution and DMSO in total and 10 µL of substrate solution (800 µM) were added and 
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thoroughly mixed. The reaction was initiated by adding 5 µL of enzyme solution 
(100 U/mL). The final concentration of the substrate in well was 40 µM (= 1.00 KM), of 
DMSO was 6 % and of HT was 2.5 U/mL. The value of KM was taken from the original 
assay.37  The reactions were followed over 10 min. All experiments were performed in 
duplicates. 
7.3.7 Human leukocyte elastase inhibition assay 
 The HLE assay38 was based on spectrosphotometric measurements of the 
released pNA at wavelength 405 nm and 25 ºC (the reaction scheme in Figure 7, 
page 25).  
 Assay buffer was 50 mM sodium phosphate buffer, pH 7.8.  
 100 µg/mL enzyme stock solution was prepared in 100 mM sodium acetate 
buffer, pH 5.5.  
 The substrate MeO-Suc-Ala-Ala-Pro-Val-pNA stock solution with the 
concentration of 50 mM was made in DMSO and assay buffer. The final concentration 
of the substrate in this stock solution was 2 mM and 10 % of DMSO. 
 The inhibitor stock solution was prepared with DMSO.  
 Into each well containing 890 µL assay buffer, 10 µL of the inhibitor solution 
and DMSO in total and 50 µL of substrate solution were added and thoroughly mixed. 
The reaction was initiated by adding 50 µL of enzyme solution. The final concentration 
of the substrate was 100 µM (= 1.85 KM) and the final concentration of DMSO was 
1.5 %. The conclusive concentration of HLE was 0.08 µM (depend on relative activity 
of enzyme). Dilution of enzyme solution to required concentration had to be done 
directly before every measurement in cold assay buffer. The value of KM was taken 
from the original assay.37 The reactions were followed over 10 min. All experiments 
were performed in duplicates or once at 10 different concentrations of a compound. 
 Due to the poor solubility of imidazole compounds derived from N-protected 
cyclohexylalanine was this assay optimized and compounds were measured in the 
presence of 2.5 % of DMSO. In each cuvette, there was 880 µL of assay buffer and 
20 µL of the inhibitor solution and DMSO in total and 50 µL of substrate solution.  
The final concentration of the substrate in the cuvette was still 100 µM (= 0.96 KM), 
while the conclusive concentration of DMSO was 2.5 %. The value of KM was 
determined. Determination and optimization details are described at page 35. 
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7.4 Enzyme kinetic evaluation of inhibitory activity 
 Data evaluations according to the following equations (graphs and results) were 
performed by the author of the thesis in GraFit - data analysis software for Windows. 
Chemical structures were made by the author of the thesis in ChemDraw® Professional - 
chemistry software. 
 Progress curves obtained in the kinetic experiments reflects the product 
formation during the measurement.  
In each measurement, the product formation of the control (100 %) was used to 
calculate the product formation in the presence of the inhibitor (%). The half-maximal 
inhibitory concentration (IC50) values can be calculated from the percentile activity 
according to the equation 1 (Figure 15, page 38). A value of activity for another 
concentration of inhibitor can be estimated from the IC50 according to the same 
equation.39 
Analysis of the progress curves depends on the binding mode of the inhibitor. In 
the course of this thesis, it was distinguished between reversible and irreversible 
inhibition, and the corresponding evaluation was performed as described below.39  
7.4.1 Reversible inhibition 
 The enzymatic reaction begins with the formation of the enzyme-substrate (ES) 
complex from the substrate (S) and the free enzyme (E). This reaction is quantified by 
the dissociation constant KS. Reversible formation of the enzyme-inhibitor (EI) complex 
is driven by non-covalent interactions between the enzyme and the inhibitor and can be 
divided into three modes. The first competitive mode is described by inhibitor binding 
to enzyme, in direct competition with the substrate. The equilibrium between EI 
complex and free enzyme and inhibitor molecules is determinated by the dissociation 
constant Ki. Noncompetitive inhibitors display binding affinity for both the free enzyme 
and the ES complex. In that case, another dissociation constant Ki for enzyme-
inhibitor-substrate (EIS) complex has to be described. The constant defines the effect 
of the inhibitor to enzyme affinity to the substrate. The last uncompetitive inhibitor 
binds exclusively to the ES complex.19 The general mechanism is shown in Figure 8.  
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Figure 8: Scheme of reversible inhibition.19  
E is the enzyme, S is the substrate, I is the inhibitor, P is the product and KS, Ki, Ki and 
KS are the dissociation constants. The scheme was made by the author of the thesis 
according to literature sources.19 
 
 Reversible inhibition is represented by linear progress curves of the product 
formation. Linear regression can be used for the evaluation as shown in Figure 9. 
 
 
Figure 9: Progress curves at presence of reversible inhibitor.  
Inhibition of human leukocyte elastase by an imidazole compound derived from  
N-protected cyclohexylalanine (3161). The enzyme activity depends on the 
concentration of the inhibitor. The progress curves can be analyzed by linear regression. 
 
 Relative activity (v) of the enzyme at individual inhibitor concentrations was 
calculated according to the equation 2 (Figure 15, page 38) and used for determination 
of IC50 values by two different models. IC50 values were obtained by non-linear 
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regression according to same equation, where v is the reaction rate in the presence of the 
inhibitor, vo is the rate in the absence of the inhibitor, x indicates an imbalance in the 
reaction stoichiometry.39  
 The second method to calculate the IC50 value was based on the same equation, 
but required that the reaction stoichiometry is 1:1, thus x = 1. The equation is simplified 
to a two-parameter equation.39 The graphical representation of both methods is shown in 
Figure 10 with compound 3161. 
 
Figure 10: IC50 determination by two different methods.  
Relative enzyme activities plotted against inhibitor concentrations. Upper: A three-
parameter equation was used. Lower: A two-parameter equation was used.  
 The obtained results are not comparable with different assays because IC50 
values depend on the substrate concentration. For comparability, IC50 values should be 
corrected by the factor of (1 + [S]/KM), where [S] is the substrate concentration and KM 
is the Michaelis-Menten constant. In general, the KM value is determined under the 
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assay conditions and characterizes the affinity of the enzyme for the specific substrate 
under these conditions. The conversion of IC50 values to Ki values is based on the 
Cheng-Prusoff equation 3 (Figure 15, page 38) which is valid for a competitive enzyme 
inhibition.19 
7.4.2 Irreversible inhibition 
 Irreversible inactivators form a covalent bond after the nucleophilic attack to the 
target enzyme which results in a time-dependent inhibition. Hyperbolic progress curves 
are expected and can be analyzed by non-linear regression using the equation 4 (Figure 




Figure 11: Progress curves in presence of irreversible inhibitor.  
A concentration-dependent inhibition of cathepsin B by 3167. The product formation 
was monitored in the presence of different inhibitor concentrations. The progress curves 
were analyzed by non-linear regression. 
 The rate at which the enzyme is inactivated is determined by the first-order rate 
constant kobs according to the equation 4 (Figure 15, page 38). First-order rate constant 
of inactivation (kinac) defines the maximum rate of inactivation that is achieved at 
infinite concentration of inhibitor. 19 
 For evaluation, the obtained kobs values were plotted versus increasing inhibitor 
concentrations to obtain kobs/[I] values. From kobs/[I], the second order rate parameter 
kinac/Ki can be calculated. The Ki defines the concentration of inhibitor that yields a rate 
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of inactivation that is equal to ½ kinac. If the measured inhibitor concentrations are below 
Ki, the linear dependence of kobs/[I] can be observed and kinac/Ki can be calculated 
according to the equation 5 (Figure 15, page 38), where the inhibitor concentration is 
not included in the denominator compared to the equation 6 (Figure 15, page 38). Yet, 
non-linear regression is performed in case the used inhibitor concentrations are about 
the Ki to obtain the kinac/Ki according to the equation 6 (Figure 15, page 38). Examples 
of these different types of evaluations are given in Figure 12.19 
 
 
Figure 12: The values kobs plotted against the different concentrations of the inhibitor. 
Inactivation of cathepsin K by 3110. Upper: The inhibitor concentrations are below Ki. 
Lower: The inhibitor concentrations are around the Ki. 
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7.4.3 Determination of the Michaelis-Menten constant 
 The Michaelis-Menten constant (KM) is the substrate concentration at which the 
reaction rate is at half of the maximum. It characterizes the affinity of the enzyme for 
the specific substrate under the specific assay conditions. 
The tested imidazole compounds derived from N-protected cyclohexylalanine 
showed limited solubility during measurements with HLE. Therefore, assay conditions 
were optimized by increasing the final concentration of DMSO from 1.5 % to 2.5 %. 
Thus, a new KM value had to be determined.  
HLE activity was assayed over 10 minutes with 20 different substrate 
concentrations in triplicate measurements. The chromogenic substrate used in the HLE 
assay was MeO-Suc-Ala-Ala-Pro-Val-pNA. The assay was carried out at pH 7.8 and 
25 °C. 
 For KM determination is necessary to obtain the steady-state velocities (vs) of 
progress curves at each measured substrate concentration. The KM was calculated to be 
104.11 ± 7.13 µM by plotting reaction rate (steady-state velocity) against substrate 
concentration and using nonlinear regression according to the Michaelis-Menten 
equation (equation 7, Figure 15, page 38). Graphs and kinetic evaluation were made by 
the author of the thesis in GraFit - data analysis software for Windows (Figure 14).  
 In the course of this thesis second determination of KM by Hanes-Woolf plot 
(Figure 13 and 14) was performed. This linear method is less accurate, but easier for 
visualization. The Hanes-Woolf plot, where [S]/vs is plotted versus substrate 
concentration is given in Figure 14.  Linear regression gave the KM value of 
99.18 ± 6.71 µM.40 
This result can be compared with the KM value of 54.05 µM from in the before 
used HLE assay. A higher KM value means, that a higher substrate concentration is 
needed to reach half of the maximum rate, reflecting a decreased enzyme affinity for the 
substrate. An increase in DMSO from 1.5 % to 2.5 % increased the KM value almost 
twice. The reduced affinity of HLE for the MeO-Suc-Ala-Ala-Pro-Val-pNA substrate 
























Figure 13: Determination of the Michaelis-Menten constant 
Upper: Plotting reaction rate (steady-state velocity - vs) against substrate concentration 
[S] by using nonlinear regression according to the Michaelis-Menten equation (equation 
7, Figure 15, page 38) vmax is maximum velocity obtained at infinite substrate 
concentration, KM is the Michaelis-Menten constant. Lower: Linear evaluation by 
Hanes-Woolf plot, where [S]/vs is plotted versus substrate concentration. Figures were 









Figure 14: Result of Michaelis-Menten constant determination.  
For the HLE-catalyzed cleavage of the MeO-Suc-Ala-Ala-Pro-Val-pNA. HLE was 
assayed spectrophotometrically in cuvettes at 405 nm and at 25 °C. Assay buffer was 
50 mM sodium phosphate buffer, pH 7.8. Final DMSO concentration was 2.5 %. 
20 various substrate concentrations were measured in triplicates for 10 minutes. Upper: 
Plot of steady-state reaction rates (vs) as a function of substrate concentration [S]. 
Michaelis-Menten constant (KM) value of 104.1 ± 7.1 µM was obtained. Lower: Hanes-
Woolf plot, where [S]/vs is plotted versus substrate concentration. KM value of 
99.18 ± 6.71 µM was obtained. Graphs and kinetic evaluation were made by the author 
of the thesis in GraFit - data analysis software for Windows. 
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7.4.4 General equations 
1. IC50 = [I] (
𝑣0
𝑣
 −  1)⁄   
 





)⁄    
  









𝐾i × (1 + [S] 𝐾M⁄ )




𝐾i × (1 + [S] 𝐾M⁄ )+ [I]
 
 




Figure 15: General equations. 
Equation 1: Relative activity and IC50 calculation. IC50 is the half-maximal inhibitory 
concentration, [I] is the inhibitor concentration, v is the reaction rate in the presence of 
the inhibitor (%), v0 is the reaction rate in the absence of the inhibitor (100 %). 
Equation 2: Three-parameter equation. v is the reaction rate in the presence of the 
inhibitor (%), v0 is the rate in absence of the inhibitor (100 %), IC50  is the half-maximal 
inhibitory concentration, [I] is the inhibitor concentration and x is a parameter for 
reaction stoichiometry. 
Equation 3: Cheng-Prusoff equation. Ki is the inactivation constant, [S] is the substrate 
concentration and KM is the Michaelis-Menten constant. 
Equation 4: Non-linear regression and kobs evaluation. [P] is the product concentration, 
vi is the initial rate, kobs is the observed first-order rate constant, t is time and d is the 
offset. 
Equations 5 and 6: kinac/Ki evaluation. kobs is the observed first-order rate constant, Ki is 
inactivation constant, [I] inhibitor concentration, [S] the substrate concentration and KM 
the Michaelis-Menten constant. 
Equation 7: Michaelis-Menten equation. v is the reaction rate, vmax is maximum velocity 
obtained at infinite substrate concentration, [S] is the substrate concentration and KM is 
the Michaelis-Menten constant. 
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8 RESULTS 
8.1 Imidazole compounds derived from N-protected 
cyclohexylalanine 
 First group of tested substances was synthesized by Jim Küppers, the member of 
prof. Gütschow's group. The imidazole core in these compounds replaces the carboxylic 
group of the benzyloxycarbonyl-protected cyclohexylalanine.  
 Five derivatives, in which the imidazole structure is once or twice substituted, 
were included to measurement. Double measurements of each tested compound in final 
concentration 5 µM did not show sufficient inhibition of cathepsins B, L, K and S.  
We set the limit for significant inhibition of 70 % of enzyme activity at a compound 
concentration of 5 µM. However, the HLE assays revealed interesting results for the 
evaluated compounds. Four out of five compounds - 2573, 3161, 3162 and 3181 were 
identified as possible selective inhibitors for this enzyme. Because of the inhibitory 
potential on HLE, an additional serine protease - HT, was also investigated.  
No inhibition of HT was observed. 
All five compounds showed problems with solubility at 5 µM under the original 
HLE assay conditions. Therefore, the final DMSO concentration was increased from 
1.5 % to 2.5 %. Under these conditions, inhibitory potential of those four compounds 
was discovered. But modifying the assay conditions led to the need for determining a 
new KM value as described below (page 35). 
In addition to solubility problems, all measured substances showed also some 
kind of instability during the stock solution preparation. Plastic Eppendorf tubes should 
not be used for preparation because of a possible adsorption of compounds at the 
surface leading to the subsequent loss of inhibitory activity. Even when dark brown 
glass vials were used a slight loss of activity was observed, so it is always necessary to 
prepare fresh solutions. With regard to the chemical structure, chemical decomposition 
is not assumed, but rather some physical instability, such as adsorption to a particular 
surface as mentioned. The results are given below in Table 3. 
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Table 3: Enzyme inhibition by imidazole compounds derived from N-protected 
cyclohexylalanine. 
№ Formula 
Enzyme activity in presence of at 5 µM 
inhibitor (%)a 








































97 92 104 91 101 98 
For footnote, see the next page. 
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a All measurements were performed in duplicates. Cathepsin B (cat B), cathepsin L 
(cat L), cathepsin K (cat K) and cathepsin S (cat S) were assayed over 60 min. Human 
leukocyte elastase (HLE) and human thrombin (HT) assays were followed over 10 min. 
Differences between absorbances or fluorescences at the beginning and at the end of the 
assay were used for determination of the final product concentration. The values of the 
control reactions were set to 100 %. 
b Enzyme activity lower than 20 % was designated as a limit for subsequent 
concentration-dependent measurements. 
c Reactions were measured in duplicates using two different concentrations (6 µM, 
9 µM) of the inhibitor. Enzyme activity at 5 µM of the compound was calculated from 
data obtained at the applied concentration according to the equation 1 (Figure 15, 
page 38). 
 
Because compounds 2573, 3161, 3162 and 3181 at 5 µM caused the HLE 
activity of less than 20 %, concentration-dependent measurements were performed. 10 
different concentrations of each tested compound were investigated. Since the 10 min 
progress curves were linear, compounds can be considered as reversible inhibitors. The 
relative activity was calculated from linear evaluation at each concentration according 
to the equation 1 (Figure 15, page 38). Non-linear three-parameter regression according 
to the equation 2 (Figure 15, page 38) was used for determination of IC50 values. The 
same analysis was used in the study focused on inhibition of HLE by Brunsvicamides 
A-C.38 Parameter x indicates an imbalance in the reaction stoichiometry. Therefore, the 
enzyme and the substrate do not react together in a proportion 1:1, but there is probably 
some other interaction in the reaction. Our data were also analyzed by non-liner 
regression using a two-parameter equation, where parameter x equals 1, but our data did 
not fit so much in this equation. To consider assay conditions and to get more 
comparable results, IC50 values were related by the factor containing KM and substrate 
concentration. 
The results obtained by both methods are included in Table 4. Three compounds, 
3161, 3162 and 3181, were identified as selective reversible inhibitors for HLE with 
IC50 ˂ 2.5 µM. The progress curves showed a time- and concentration-dependent 
reversible inhibition. The compound 3161 (IC50 (1 + [S] 𝐾M⁄ )⁄  = 0.60 ± 0.03 µM), 
where the imidazole ring is substituted with methyl and phenyl, was identified as the 
best selective inhibitor of HLE out of this series of compounds. The imidazole derivate 
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with two phenyl substituents 3162 (IC50 (1 + [S] 𝐾M⁄ )⁄  = 0.96 ± 0.06 µM) and the 
thienyl-substituted 3181 (IC50 (1 + [S] 𝐾M⁄ )⁄  = 1.16 ± 0.02 µM) showed a somewhat 
weaker inhibitory potency towards the HLE. Compound 2573, where the imidazole is 
substituted by one phenyl residue, showed insufficient inhibition characterized by IC50 
˃ 2.5 µM. For 3182, inhibition was not observed. Because of compound 3182, 
imidazole compounds derived from N-protected cyclohexylalanine cannot be generally 
considered as inhibitors of HLE. Graphs and detailed summary of the individual 
inhibitors with IC50 ˂ 2.5 µM are given below in Figures 16, 17, 18. 
Table 4: Human leukocyte elastase inhibition by promising compounds 2573, 3161, 
3162, 3181.a 
№ Three-parameters model Two-parameters model 
 















3.02 ± 0.06 9.33 ± 1.98 1.55 ± 0.03 7.18 ± 2.92 1 3.66 ± 1.49 
3161 
 
1.18 ± 0.06 2.69 ± 0.27 0.60 ± 0.03 0.71 ± 0.20 1 0.36 ± 0.10 
3162 
 
1.88 ± 0.12 3.76 ± 0.75 0.96 ± 0.06 1.37 ± 0.48 1 0.70 ± 0.24 
3181 
 
2.27 ± 0.04 5.05 ± 0-47 1.16 ± 0.02 2.21 ± 0.84 1 1.13 ± 0.84 
a 10 different concentrations of compounds were measured once every 10 minutes and 
values of the half-maximal inhibitory concentration (IC50) were evaluated by non-linear 
regression with two- and three-parameters model according to the equation 2 (Figure 








   
Figure 16: Inhibition of human leukocyte elastase by compound 3161.  
The substrate concentration was 100 µM (0.96 KM) Upper: Product formation in the 
presence of different inhibitor concentrations. The progress curves were analyzed by 
linear regression. Lower: The relative activities were plotted against the inhibitor 
concentrations. Lower left: The half-maximal inhibitory concentration (IC50) of 
1.18 ± 0.06 µM was obtained by non-linear regression using the equation 2 (Figure 15, 
page 38), where x = 2.69 ± 0.27. Lower right: An IC50 value of 0.71 ± 0.20 µM was 
obtained by non-linear regression using the same equation (x = 1). Graphs and kinetic 













































































































   
Figure 17: Inhibition of human leukocyte elastase by compound 3162.  
The substrate concentration was 100 µM (0.96 KM). Upper: Product formation in the 
presence of different inhibitor concentrations. The progress curves were analyzed by 
linear regression. Lower: The relative activities were plotted against the inhibitor 
concentrations. Lower left: The half-maximal inhibitory concentration (IC50) of 
1.88 ± 0.12 µM was obtained by non-linear regression using the equation 2 (Figure 15, 
page 38), where x = 3.76 ± 0.75. Lower right: An IC50 value of 1.37 ± 0.48 µM was 
obtained by non-linear regression using the same equation (x = 1). Graphs and kinetic 












































































































    
Figure 18: Inhibition of human leukocyte elastase by compound 3181.  
The substrate concentration was 100 µM (0.96 KM) Upper: Product formation in the 
presence of different inhibitor concentrations. The progress curves were analyzed by 
linear regression. Lower: The relative activities were plotted against the inhibitor 
concentrations. Lower left: The half-maximal inhibitory concentration (IC50) of 
2.27 ± 0.04 µM was obtained by non-linear regression using the equation 2 (Figure 15, 
page 38), where x = 5.05 ± 0.47. Lower right: An IC50 value of 2.21 ± 0.84 µM was 
obtained by non-linear regression using the same equation (x = 1). Graphs and kinetic 
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8.2 2-Phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)one derivatives 
 Other group of tested substances were synthesized by Jim Küppers as well. The 
main structure of this group belongs to compound 3173, 2-phenyl-7,8-
dihydroimidazo[1,2-a]pyrazin-6(5H)one. Other compounds are substituted at position 8. 
Exception is compound 3178, where pyrazine has one more carbon added in the ring. 
Just like the previous group, these compounds were at first tested on cathepsins and 
HLE. None of the tested substances at concentration 5 µM has shown any inhibitory 
potency against the assayed enzymes. Further testing was not performed.  
All experiments were conducted without any problems with stability or solubility.  
The results are given below in Table 5. 
Table 5: Enzyme inhibition by derivatives of 2-phenyl-7,8-dihydroimidazo[1,2-
a]pyrazin-6(5H)one. 
№ Formula 
Enzyme activity at 5 µM (%)a 
































99 96 97 86 104 
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97 95 89 86 94 
a All measurements were performed in duplicates at the compound concentration of 
5 µM. Cathepsin B (cat B), cathepsin L (cat L), cathepsin K (cat K) and cathepsin S 
(cat S) were assayed over 60 min. Human leukocyte elastase (HLE) inhibition assays 
were followed over 10 min. Differences between absorbances or fluorescences at the 
beginning and at the end of the assay were used for determination of the final product 
concentration.  The values of the control reactions were set to 100 %. 
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8.3 ,-Unsaturated peptidomimetic compounds 
 The next tested compounds were synthesized by other member of our group, 
Christian Breuer. The main structural feature of this group is an ,-unsaturated 
carbonyl moiety integrated into a peptide structure. These compounds were synthesized 
as potential cat B inhibitors. Therefore, they were tested only on cathepsins. The results 
have not shown any significant inhibition (Table 6). 




















5 97 93 75b 93 b 
10 97 96 67 b 84 b 








5 98 98 89 95 
10 95 95 78 90 








5 88 89 89 81 
10 95 94 87 66 
20 90 92 74 60 
For footnote, see the next page. 
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a All measurements with cathepsin B (cat B), cathepsin L (cat L), cathepsin K (cat K) 
and cathepsin S (cat S) were performed in duplicates at the compound concentration of 
5, 10 and 20 µM. Reactions were followed over 60 min. Differences between 
absorbances or fluorescences at the beginning and at the end of the assay were used for 
determination of the final product concentration. The values of the control reactions 
were set to 100 %. 
b The measurements shown here were performed by Carina Lemke. 
8.4 Carbamate 
 The chemotype of peptidic carbamate inhibitors has been developed in the prof. 
Gütschow's group as irreversible inhibitors of cysteine proteases, in particular cat B. 
Carbamate 3167 was synthesized by Jim Küppers. In the course of this thesis, inhibitory 
activity of synthesized compound was investigated on cat B. Further enzyme assays will 
be performed by other group members. The compound at the concentration of 20 µM, 
decreased the enzyme activity to 66 %. Concentration-dependent measurement at 
5 different concentrations was performed. From the obtained values, compound 3167 
can be considered as an irreversible cat B inhibitor. Results are given in Table 7 and 
Figure 19.  












66 12.44 ± 0.49 
a Measurement was performed duplicates at 20 µM compound concentration. Reaction 
was followed over 60 min. Differences between absorbances or fluorescences at the 
beginning and at the end of the assay were used for determination of the final product 
concentration. The values of the control reactions were set to 100 %. 
b Sample was measured in duplicates at inhibitor concentration of 10, 20, 30, 40 and 
50 µM. Observed first-order rate constant (kobs) values calculated according to the 
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equation 5 (Figure 15, page 38) were plotted against the inhibitor concentration. The 
second order rate parameter (kinac/Ki) was determined by the equation 6 (Figure 15, 
page 38). S.E. is a standard error. The substrate concentration was 500 µM (0.45 KM).
35 
 
      
Figure 19: Inhibition of human cathepsin B by 3167.  
Left: Product formation in the presence of different inhibitor concentrations. From the 
top to the bottom: 0 µM (black line), 10 µM (red line), 20 µM (green line), 30 µM (dark 
yellow line), 40 µM (dark blue line), 50 µM (light blue line). The progress curves were 
analyzed by nonlinear regression. Right: The observed first-order rate constant (kobs) 
from duplicate measurements were plotted against the inhibitor concentrations [I].  
A kobs/[I] value of 8.58 ± 0.34 µM
-1s-1 was obtained by linear regression according to 
the equation 5 (Figure 15, page 38). The second order rate parameter (kinac/Ki) of 
12.44 ± 0.49 µM-1s-1 was obtained. Kinetic evaluation and graphs were made by the 
author of the thesis in GraFit - data analysis software for Windows. 
8.5 N,N-dibenzylcrotonamide derivative 
 Compound 3110, an N,N-dibenzylcrotonamide derivative, was synthesized by 
Christian Breuer as potential cat K inhibitor. It contains an -unsaturated Michael 
acceptor substructure again, which is investigated as a moiety useful for cathepsin 
inhibition.41 Only concentration-dependent measurements at cat K were performed in 
the course of this thesis. Further enzyme assays will be performed by other group 
members. Data were obtained from the cat K inhibition assay, which indicate compound 
3110 to be an irreversible cat K inhibitor. The result can be seen in Table 8 and in 
Figure 20.  
t (min)
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Table 8: Cathepsin K inhibition by compound 3110.a 
№ Formula 
kinac/Ki ± S.E. 
(µM)b 








2293 ± 241 5940 ± 1717 
a Measurements were performed in duplicates at the compound concentrations of 1, 2, 3, 
4, 5 µM. Reactions were followed over 60 min. The observed first-order rate constant 
(kobs) values from product progress curves were plotted against the inhibitor 
concentration. The substrate concentration was 40 µM (3.01 KM).
35 
b The second order rate parameter (kinac/Ki) was obtained by linear regression according 
to the equation 5 (Figure 15, page 38). S.E. is a standard error. 
c kinac/Ki was obtained by non-linear regression, according to the equation 6 (Figure 15, 
page 38). 
  





Figure 20: Inhibition of human cathepsin K by 3110.  
Upper: Product formation in the presence of different inhibitor concentrations.  
The progress curves analyzed by nonlinear regression indicate irreversible inhibition. 
Lower: The observed first-order rate constant (kobs) from duplicate measurements were 
plotted against the inhibitor concentrations [I]. Lower left: A kobs/[I] value of 
160.0 ± 16.8 µM was obtained according to the equation 4 (Figure 15, page 38).  
The second order rate parameter (kinac/Ki) of 2293 ± 241 was calculated according to the 
equation 5 (Figure 15, page 38). Lower right: A kobs/[I] value of 414.5 ± 119.8 µM was 
analyzed by non-linear regression according to the equation 5 (Figure 15, page 38).  
The kinac/Ki value of 5940 ± 1717 was calculated according to the equation 6 (Figure 15, 
page 38). Kinetic evaluation and graphs were made by the author of the thesis in GraFit 
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8.6 Peptoides 
 The peptoides synthesized by Franziska Kohl represent the last tested group of 
compounds included in this thesis. A set of six peptoides, poly-N-substituted glycines, 
were tested only at cat L. No inhibition was observed. The obtained values are included 
below in Table 9. 


























































a All measurements with cathepsin L (cat L) were performed in duplicates at the 
peptoide concentration of 1 µM. Reactions were followed over 60 min. Differences 
between absorbances or fluorescences at the beginning and at the end of the assay were 
used for determination of the final product concentration. The values of the control 
reactions were set to 100 %.  
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9 DISCUSSION 
 In this diploma thesis, there is presented the enzyme inhibition activity of new 
potential inhibitors against human cathepsins B, L, S, K, which belong to cysteine 
proteases, as well as against representatives of serine proteases, HLE and HT. 
 The imidazole compounds derived from N-protected cyclohexylalanine were 
synthesized and their inhibitory potential was unknown. During the investigation, a 
reversible inhibition of HLE was observed. The non-covalent inactivation and the 
concentration-dependent inhibition were concluded from linear progress curves. As a 
sign of selectivity, the compounds did not demonstrate inhibition of tested cathepsins 
and HT. All measured substances showed some kind of instability during the stock 
solution preparation. Plastic Eppendorf tubes should not be used for storage of the 
compounds' solution, because of subsequent loss of inhibitory activity. Even when dark 
brown glass vials were used, a slight loss of activity was observed. So it was always 
necessary to prepare fresh solutions. With regard to the chemical structure, chemical 
decomposition is not assumed, but rather some physical instability, such as adsorption 
to a particular surface. The compounds also showed problems with solubility at 5 µM 
under the original HLE assay conditions. Therefore, the final DMSO concentration was 
increased (from 1.5 % to 2.5 %) and a new KM value was determined. The best inhibitor 
was compound 3161 containing the imidazole substituted by methyl and phenyl 
residues (IC50 (1 + [S] 𝐾M⁄ )⁄  = 0.60 ± 0.03 µM). The other compounds from this group 
also act as reversible inhibitors, except for compound 3182. There was no inhibition 
observed. Because of this last compound, the general inhibitory potential of this group 
cannot be concluded. But some similar derivatives should be prepared and investigated 
in the future. 
The 2-phenyl-7,8-dihydroimidazo[1,2-a]pyrazin-6(5H)-one compounds were 
also synthesized with unknown inhibitory potential. In this case, inhibition was not 
observed. The bicyclic structure containing the imidazole seems to be less appropriate 
for HLE inhibition than the monocyclic imidazole moiety in the previous group.   
The irreversible inhibition of cysteine proteases was expected for the  
,-unsaturated peptidomimetic compounds, based on their Michael acceptor 
substructure.41 But the inhibition of cathepsins B, L, K and S by this group of 
compounds was not observed.    
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Compounds containing the carbamate structure have been developed in the prof. 
Gütschow's group as irreversible inhibitors of cysteine proteases. In the literature, 
similar compounds can be found, which are inhibiting some cysteine cathepsins.42–44  
In the course of this thesis, carbamate 3167 was investigated as potential cat B inhibitor. 
Kinetic evaluation demonstrated the concentration-dependent activity, where non-linear 
progress curves and kinac/Ki value of 12.44 ± 0.49 µM
-1s-1 were observed. From these 
results, this compound can be considered as an irreversible inhibitor of cat B. The data 
also confirm carbamate derivatives as a promising approach for the cysteine inhibitor 
development. 
The N,N-dibenzylcrotonamide derivative also contains an -unsaturated 
Michael acceptor substructure, as in case of the ,-unsaturated peptidomimetic 
compounds. The inhibitory activity of compound 3110 belonging to this group was 
investigated on cat K. The observation of concentration-dependent measurement with 
non-linear progress curves and the kinac/Ki value of 2293 ± 241 µM
-1s-1 supports the 
irreversible inhibition. The results also confirm Michael acceptors as an appropriate 
substructure in the cysteine inhibitor development. 
 The peptoides were synthesized and their inhibitory potential was unknown. 
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10 CONCLUSION 
In summary, some potent inhibitors have been found. In case of imidazole 
derivatives, four compounds have been characterized as reversible inhibitors.  
The compound 3167 has shown that the use of the carbamate structure is a useful 
approach in development of cat B inhibitors. But because only one carbamate 
compound was included in this project, it is necessary to evaluate more carbamate-type 
compounds for extended conclusions. The N,N-dibenzylcrotonamide derivative (3110) 
as observed cat K inhibitor offers possibilities of Michael acceptor elements within the 
structures of the irreversible cat K inhibitors. Further representatives of this chemotype 
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